Edition:
United Kingdom

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

5.97USD
16 Nov 2018
Change (% chg)

$0.21 (+3.65%)
Prev Close
$5.76
Open
$5.71
Day's High
$6.14
Day's Low
$5.64
Volume
1,251,464
Avg. Vol
301,522
52-wk High
$30.35
52-wk Low
$3.34

Summary

Name Age Since Current Position

Patrick LePore

63 2018 Independent Chairman of the Board

Timothy Crew

53 2018 Chief Executive Officer, Director

Martin Galvan

66 2017 Chief Financial Officer, Vice President - Finance

John Abt

53 2018 Vice President and Chief Quality and Operations Officer

Maureen Cavanaugh

58 2018 Senior Vice President and Chief Commercial Operations Officer

Grant Brock

2018 Vice President - Operations

Robert Ehlinger

60 2011 Vice President - Logistics, Chief Information Officer

Samuel Israel

56 2018 General Counsel, Chief Legal Officer

John Kozlowski

46 2018 Chief of Staff and Strategy Officer

Jeffrey Farber

57 2018 Director

Albert Paonessa

58 2017 Director

John Chapman

63 2018 Independent Director

David Drabik

50 2011 Lead Independent Director

Paul Taveira

58 2012 Independent Director

Biographies

Name Description

Patrick LePore

Mr. Patrick G. LePore is an Independent Chairman of the Board of the Company effective July 1, 2018, He has served as chairman, CEO and president of Par Pharmaceuticals, Inc., until the company's acquisition by private equity investor TPG in 2012. He remained as chairman of the new company where he led the sale of the company to Endo Pharmaceuticals. LePore began his career with Hoffmann LaRoche. Later, he founded Boron LePore and Associates, a medical communications company, which he took public and was eventually sold to Cardinal Health. He is a member of the board of directors of PharMerica and Innoviva, and is a trustee of Villanova University. LePore earned his bachelor's degree from Villanova University and Master of Business Administration from Fairleigh Dickinson University.

Timothy Crew

Mr. Timothy C. Crew is the Chief Executive Officer, Director of the Company. Mr. Crew has more than 25 years of experience in the generic and branded pharmaceutical industries, most recently serving as Chief Executive Officer of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017. Previously, he worked for eight years at Teva Pharmaceuticals Industries Ltd. (“Teva”), where he served as Senior Vice President and Commercial Operating Officer of the North American Generics division, the world’s largest generic operation with multibillion dollars of annual sales. Before that, he was Teva’s Vice President, Alliances and Business Development. From 2001 to 2004, Mr. Crew was Executive Vice President, North America, for Dr. Reddy’s Laboratories Ltd. Mr. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.

Martin Galvan

Mr. Martin P. Galvan, CPA, is the Chief Financial Officer, Vice President - Finance, Treasurer of the Company. Most recently, he was Chief Financial Officer of CardioNet, Inc., a medical technology and service company. From 2001 to 2007, Mr. Galvan was employed by Viasys Healthcare Inc., a healthcare technology company that was acquired by Cardinal Health, Inc. in June 2007. Prior to the acquisition, he served as Executive Vice President, Chief Financial Officer and Director Investor Relations. From 1999 to 2001, Mr. Galvan served as Chief Financial Officer of Rodel, Inc., a precision surface technologies company in the semiconductor industry. From 1979 to 1998, Mr. Galvan held several positions with Rhone-Poulenc Rorer Inc., a pharmaceutical company, including Vice President, Finance — The Americas; President & General Manager, RPR Mexico & Central America; Vice President, Finance, Europe/Asia Pacific; and Chief Financial Officer, United Kingdom & Ireland. Mr. Galvan began his career with the international accounting firm Ernst & Young LLP. He earned a Bachelor of Arts degree in economics from Rutgers University and is a member of the American Institute of Certified Public Accountants.

John Abt

Mr. John M. Abt is the Vice President and Chief Quality and Operations Officer of the Company. Prior to joining the Company, Mr. Abt held senior level positons in both quality and operations and has extensive knowledge in pharmaceutical manufacturing, quality, strategy, business improvement and site transformation. He most recently served as Teva Pharmaceuticals’ Vice President Global Quality Strategy, overseeing the development and implementation of strategy and associated initiatives for the global quality organization. Before that, he held a number of leadership positions of increasing responsibility in operations, continuous improvement, quality systems and compliance. He earned his Doctorate in Business Administration from Temple University, Masters of Administrative Science in Business Management from Johns Hopkins University and a Bachelor of Science in Biochemistry from Niagara University. Vice President and Chief Quality and Operations Officer.

Maureen Cavanaugh

Ms. Maureen M. Cavanaugh is the Senior Vice President and Chief Commercial Operations Officer of the Company. For the last 11 years, Cavanaugh worked for Teva PharmaceuticalsUSA, most recently as senior vice president, chief commercial officer, North America Generics, where she had oversight responsibility for leading trade sales, new product planning and portfolio management teams, as well as the long range planning and strategy development processes for the company's U.S. generics business. Earlier at Teva, she was general manager, U.S. generics with responsibility for sales and marketing and, before that, held a variety of positions in marketing and customer operations. Cavanaugh previously served as senior director, marketing for PAR Pharmaceuticals; and, director, product management and market research for Sandoz (the generic drug division of Novartis). Prior to that, she held a number of finance, sales and marketing operations positions at Bristol Myers-Squibb.

Grant Brock

Mr. Grant Brock is the Vice President - Operations of the Company. Brock has held a number of senior level positions in operations. Before joining Lannett, he was vice president operations for Aprecia Pharmaceuticals. He previously served as senior vice president operations for Custom Powder Systems, and before that held several roles of increasing responsibility in manufacturing and engineering at Teva Pharmaceuticals.

Robert Ehlinger

Mr. Robert Ehlinger is the Vice President - Logistics, Chief Information Officer of the Company. In June 2011, Mr. Ehlinger was promoted to Vice President of Logistics and Chief Information Officer. Prior to joining Lannett, Mr. Ehlinger was the Vice President of Information Technology at MedQuist, Inc., a healthcare services provider, where his career spanned 10 years in progressive operational and technology roles. Prior to MedQuist, Mr. Ehlinger was with Kennedy Health Systems as their Corporate Director of Information Technology supporting acute care and ambulatory care health information systems and biomedical support services. Earlier on, Mr. Ehlinger was with Dowty Communications where he held various technical and operational support roles prior to assuming the role of International Distribution Sales Executive managing the Latin America sales distribution channels. Mr. Ehlinger received a Bachelor’s of Arts degree in Physics from Gettysburg College in Gettysburg, PA.

Samuel Israel

Mr. Samuel H. Israel is the General Counsel and Chief Legal Officer of the Company. Mr. Israel is the Vice President, General Counsel, Chief Legal Officer of the company. Prior to joining Lannett, Mr. Israel was a partner with Fox Rothschild LLP, a national, full-service law firm, with 22 offices that provide services in more than 60 practice areas, since 1998. He served as chair of the firm’s Pharmaceutical and Biotechnology Practice and handled a variety of commercial litigation matters. Mr. Israel earned a bachelor of science degree in chemical engineering from the University of Pennsylvania and a Juris Doctor degree with honors from Rutgers University School of Law.

John Kozlowski

Mr. John Kozlowski is the Chief of Staff and Strategy Officer of the Company. He played a leading role in a number of significant operational initiatives, including the integration of Kremers Urban Pharmaceuticals, Inc. and Silarx Pharmaceuticals, Inc., as well as corporate-wide efforts to optimize efficiencies. He joined the Company in 2009 as Corporate Controller, was promoted in 2016 to Vice President Financial Operations & Corporate Controller and was promoted in 2017 to Chief Operating Officer. Prior to joining the Company, Mr. Kozlowski served in senior finance and accounting roles for Optium Corporation and Finisar Australia. Mr. Kozlowski earned a Bachelor of Arts degree in finance from James Madison University and a Masters of Business Administration degree from Rider University.

Jeffrey Farber

Mr. Jeffrey Farber is the Director of the Company effective July 1, 2018. He is no longer Chairman of the Board of the Company effective July 1, 2018, . Mr. Jeffrey Farber joined the Company in August 2003 as Secretary. Since 1994, Mr. Farber has been President and the owner of Auburn Pharmaceutical (“Auburn”), a national generic pharmaceutical distributor. Prior to starting Auburn, Mr. Farber served in various positions at Major Pharmaceutical (“Major”), where he was employed for over 15 years. At Major, Mr. Farber was involved in sales, purchasing and eventually served as President of the Midwest division. Mr. Farber also spent time working at Major’s manufacturing division, Vitarine Pharmaceuticals, where he served on its Board of Directors. Mr. Farber graduated from Western Michigan University with a Bachelors of Science Degree in Business Administration and participated in the Pharmacy Management Graduate Program at Long Island University.

Albert Paonessa

Mr. Albert Paonessa, III is the Director of the Company. Mr. Paonessa is an Independent Director of the Company. In May 2017, Mr. Paonessa was appointed the CEO of KeySource Medical, a generic distributor (“KeySource”). Prior to that, Mr. Paonessa served as the President of Anda, Inc., the fourth largest distributor of generic drugs in the U.S., for over 10 years until January 2015. He previously served as Anda’s Senior Vice President of Sales and before that as Vice President of IT. Earlier, Mr. Paonessa was Vice President of Operations for VIP Pharmaceuticals, which was acquired by Anda’s parent company Andrx, in 2000. Mr. Paonessa earned a Bachelor of Arts degree in Interpersonal Communications from Bowling Green State University.

John Chapman

Mr. John C. Chapman is an Independent Director of the Company effective on effective July 1, 2018. He is a retired audit partner for KPMG LLP, where he was employed for 39 years. At KPMG, Mr. Chapman specialized in providing audit services to large complex multinational pharmaceutical and consumer market companies. During his tenure year at KPMG he served for six years as a member of the firm’s Board of Directors and for several years served as the firm’s Global Chair of Pharmaceuticals and Chemicals. Mr. Chapman earned a bachelor in business administration in accounting practice from Pace University, New York.

David Drabik

Mr. David Drabik is the Lead Independent Director of the Company. Mr. Drabik is a National Association of Corporate Directors Governance Fellow. Since 2002, Mr. Drabik has been President of Cranbrook & Co., LLC (“Cranbrook”), an advisory firm primarily serving the private equity and venture capital community. At Cranbrook, Mr. Drabik assists and advises its clientele on originating, structuring and executing private equity and venture capital transactions. From 1995 to 2002, Mr. Drabik served in various roles and positions with UBS Capital Americas (and its predecessor UBS Capital LLC), a New York City based private equity and venture capital firm that managed $1.5 billion of capital. From 1992 to 1995, Mr. Drabik was a banker with Union Bank of Switzerland’s Corporate and Institutional Banking division in New York City. Mr. Drabik graduated from the University of Michigan with a Bachelors of Business Administration degree.

Paul Taveira

Mr. Paul Taveira is an Independent Director of the Company. Mr. Taveira has been Chief Executive Officer of the National Response Corporation, an international firm specializing in environmental services, since June 2015. He previously served on the Board of Directors and as the Chief Executive Officer of A&D Environmental Services Inc., an environmental and industrial services company. From 2007 to 2009, Mr. Taveira was a Managing Partner of Precision Source LLC, a manufacturer of precision parts for various industries across the United States. From 1997 to 2007, Mr. Taveira held several positions at PSC Inc. a national provider of environmental services, including President, Vice President and Regional General Manager. From 1987 to 1997, Mr. Taveira held several management positions with Clean Harbors Inc., an international provider of environmental and energy services. Mr. Taveira graduated from Worcester State University with a Bachelor of Science degree in Biology.

Basic Compensation

Name Fiscal Year Total

Patrick LePore

129,785

Timothy Crew

1,329,780

Martin Galvan

763,745

John Abt

565,013

Maureen Cavanaugh

--

Grant Brock

--

Robert Ehlinger

406,417

Samuel Israel

1,083,840

John Kozlowski

596,314

Jeffrey Farber

247,006

Albert Paonessa

248,006

John Chapman

--

David Drabik

266,006

Paul Taveira

240,006
As Of  30 Jun 2018